- Home
- ADV vs AUPH Comparison
ADV vs AUPH Comparison
Compare ADV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- AUPH
- Stock Information
- Founded
- ADV 1987
- AUPH 1993
- Country
- ADV United States
- AUPH Canada
- Employees
- ADV N/A
- AUPH N/A
- Industry
- ADV Business Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- AUPH Health Care
- Exchange
- ADV Nasdaq
- AUPH Nasdaq
- Market Cap
- ADV 586.7M
- AUPH 1.4B
- IPO Year
- ADV N/A
- AUPH 1999
- Fundamental
- Price
- ADV $1.97
- AUPH $12.87
- Analyst Decision
- ADV Strong Buy
- AUPH Strong Buy
- Analyst Count
- ADV 1
- AUPH 3
- Target Price
- ADV $2.50
- AUPH $12.00
- AVG Volume (30 Days)
- ADV 660.2K
- AUPH 1.6M
- Earning Date
- ADV 11-06-2025
- AUPH 11-06-2025
- Dividend Yield
- ADV N/A
- AUPH N/A
- EPS Growth
- ADV N/A
- AUPH N/A
- EPS
- ADV N/A
- AUPH 0.42
- Revenue
- ADV $3,527,054,000.00
- AUPH $260,111,000.00
- Revenue This Year
- ADV N/A
- AUPH $16.92
- Revenue Next Year
- ADV N/A
- AUPH $14.43
- P/E Ratio
- ADV N/A
- AUPH $30.31
- Revenue Growth
- ADV N/A
- AUPH 25.59
- 52 Week Low
- ADV $1.04
- AUPH $6.43
- 52 Week High
- ADV $4.10
- AUPH $12.87
- Technical
- Relative Strength Index (RSI)
- ADV 63.02
- AUPH 68.86
- Support Level
- ADV $1.78
- AUPH $12.06
- Resistance Level
- ADV $1.93
- AUPH $12.82
- Average True Range (ATR)
- ADV 0.09
- AUPH 0.37
- MACD
- ADV 0.01
- AUPH -0.04
- Stochastic Oscillator
- ADV 84.93
- AUPH 93.23
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.